Article
Excerpt from the Press Release: SAN FRANCISCO, Aug. 09, 2022 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), today announced the advancement of OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), into Phase 2 clinical development for the treatment of ER+/HER2- metastatic breast cancer. “We are excited…
Read More
– Efficacy Observed with QINLOCK® was Comparable to Sunitinib with a More Favorable Safety and Tolerability Profile in GIST Patients Previously Treated with Imatinib – Excerpt from the Press Release: WALTHAM, Mass.–(BUSINESS WIRE)–Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer,…
Read More
GPH101, now called nulabeglogene autogedtemcel (nula-cel), designed to directly correct the genetic mutation that causes sickle cell disease Initial proof-of-concept data from Phase 1/2 CEDAR trial anticipated in mid-2023 Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision…
Read More
– In Adults with Non-transfusion-dependent α- or β-Thalassemia, PYRUKYND® Induced ≥1.0 g/dL Hemoglobin Increase from Baseline in 16 of 20 (80%) Patients Between Weeks 4-12 – – PYRUKYND® Safety Profile Consistent with Label for FDA-approved Indication in Pyruvate Kinase Deficiency – – Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependent α-…
Read More
Company Creates “Younger T Cells” for Fighting Cancer Using its NR2F6 Technology Excerpt from the Press Release: SAN DIEGO, Aug. 11, 2022 /PRNewswire/ — Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) announced today the filing with the United States Patent and Trademark Office of a provisional US patent application covering the Company’s novel approach for…
Read More
– The pivotal Precision-T Study is evaluating the safety and efficacy of Orca Bio’s investigational Orca-T compared to standard of care allogeneic hematopoietic stem cell transplant – – Precision-T is expected to enroll approximately 174 patients across more than 20 clinical trial sites – Excerpt from the Press Release: MENLO PARK, Calif.–(BUSINESS WIRE)–Orca Bio, a late-stage…
Read More
– NeuroSense’s support will aid EverythingALS with ground-breaking patient research in a joint effort to develop treatments – NeuroSense’s CEO to present at EverythingALS’s Expert Talk Series on August 3, 2022; To listen to Mr. Ben-Noon’s Excerpt from the Press Release: LOS ALTOS, Calif. and CAMBRIDGE, Mass., Aug. 2, 2022 /PRNewswire/ — EverythingALS, a patient-focused…
Read More
Enable Biosciences Reports Easier and Accurate SARS-CoV-2 Neutralizing Antibody Assay using Dried Blood Spot Samples Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Aug. 3, 2022 /PRNewswire/ — Scientists at Enable Biosciences report a novel method to easily, rapidly and accurately detect neutralizing antibodies against SARS-CoV-2 from dried blood spots, named “SONIA” (Split-Oligonucleotide Neighboring…
Read More
Single ascending dose (SAD) Phase 1 Study completed in Australia with a maximum dose of 2,000 mg. Pharmacokinetics (PK) were dose proportional and PK modeling and preclinical data support a 600 mg twice daily dose. There were no serious AEs (SAEs) or severe TEAEs and the maximum tolerated dose (MTD) was not reached. Initiation of…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] announced that Ipsen, SA (“Ipsen”) has issued a press release today reporting its primary analysis of the results of its Phase 3 trial of Onivyde® (irinotecan liposomal injection) as a treatment of second line small cell lung cancer (SCLC).…
Read More